Non-coding RNA profiling in BRAFV600E-mutant cutaneous melanoma models before and after Spry1 depletion

ABSTRACT: Background: Drugs directly targeting the BRAF protein and the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway have provided remarkable response rates in BRAFV600-mutant metastatic cutaneous melanoma (CM) patients. However, the occurrence of resistance persists, requiring a better understanding of molecular mechanisms underlying the treatment's response to improve therapeutic strategies. Grown evidence has linked microRNAs (miRNAs) to the biology and drug sensitivity of CM, as several of them have been demonstrated to modulate pathways driving tumor pathogenesis and immune response. Yet, the connection between specific miRNA signatures and CM-developed resistance to BRAF inhibitors (BRAFi) has not been completely elucidated. We have already demonstrated that S

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens

SUBMITTER:  

PROVIDER: E-MTAB-15185 | biostudies-arrayexpress |

SECONDARY ACCESSION(S): E-MTAB-15186

REPOSITORIES: biostudies-arrayexpress